Explore the words cloud of the SO-CMA project. It provides you a very rough idea of what is the project "SO-CMA" about.
The following table provides information about the project.
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
|Coordinator Country||United Kingdom [UK]|
|Total cost||183˙454 €|
|EC max contribution||183˙454 € (100%)|
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
|Duration (year-month-day)||from 2016-03-07 to 2019-05-29|
Take a look of project's partnership.
|1||IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE||UK (LONDON)||coordinator||183˙454.00|
Background: Food allergy affects 6% of children in the EU, and has a major impact on quality of life, nutrition, health-economics and the food production industry. Cow’s milk (CM) is a common cause, and can be particularly problematic due to the ubiquitous nature of CM in foods. Strict dietary avoidance is difficult to achieve, and unpredictable life-threatening accidental reactions are common, leading to anxiety and social restrictions for patients and families. Oral immunotherapy (OIT) has been shown to be efficacious but is not widely accepted as routine treatment, due to significant safety concerns – allergic reactions are common, and can be particularly severe in CM-OIT. Objective: To improve the safety of OIT for CM allergy. Proposed methods: WP1 - Systematic review of the literature to identify features of published OIT protocols that are associated with improved safety. WP2 - Assessment of human immune responses to candidate modified CM proteins (proven to be both non-allergenic and tolerising in murine models) as potential tools for immunotherapy. WP3. Phase 2/3 clinical trial to assess whether a sublingual pre-treatment phase can improve the safety of OIT in CM allergic children. Deliverables: 1) Systematic review to identify features of CM-OIT associated with improved safety. 2) Evidence on the immunogenicity of candidate modified CM proteins in humans, which will reflect their suitability as immunotherapy agents in the future. 3) Data relating to whether an initial sublingual phase can improve the safety of CM-OIT. 4) Pilot data on mechanisms underlying the immune-modulation induced by OIT. 5) Skills transference to the applicant to become a highly qualified independent researcher, with expertise in OIT for food allergy at an International level. 6) Consolidation of the host institution as a centre of excellence in food immunotherapy, including the potential for tolerising modified proteins to improve OIT safety and efficacy.
|year||authors and title||journal||last update|
A Martorell, E Alonso, L EcheverrÃa, C Escudero, R GarcÃa-RodrÃguez, C Blasco, J Bone, J Borja-Segade, T Bracamonte, A Claver, JL Corzo, B De la Hoz, R Del Olmo, O Dominguez, V Fuentes-Aparicio, I Guallar, H Larramona, F MartÃn-MuÃ±oz, V Matheu, A Michavila, I Ojeda, P Ojeda, M Piquer, P Poza, M Reche, P RodrÃguez del RÃo, M RodrÃguez, F Ruano, S SÃ¡nchez-GarcÃa, S Terrados, L Valdesoiro, M Vazquez-Ortiz
Oral immunotherapy for food allergy: a spanish guideline - Part 2. Immunotherapy Egg and Milk Spanish Guide (items guide)
published pages: , ISSN: 1018-9068, DOI: 10.18176/jiaci.0178
|Journal of Investigational Allergology and Clinical Immunology 27/5||2019-06-13|
Marta Vazquez-Ortiz, Paul J. Turner
Improving the safety of oral immunotherapy for food allergy
published pages: 117-125, ISSN: 0905-6157, DOI: 10.1111/pai.12510
|Pediatric Allergy and Immunology 27/2||2019-06-13|
A Martorell, E Alonso, L EcheverrÃa, C Escudero, R GarcÃa-RodrÃguez, C Blasco, J Bone, J Borja-Segade, T Bracamonte, A Claver, V De la Hoz, JL Corzo, R Del Olmo, O Dominguez, V Fuentes-Aparicio, H Larramona, F MartÃn-MuÃ±oz, V Matheu, A Michavila, I Ojeda, P Ojeda, M Piquer, P Poza, M Reche, P RodrÃguez del RÃo, M RodrÃguez, F Ruano, S SÃ¡nchez-GarcÃa, S Terrados, L Valdesoiro, M Vazquez-Ortiz
Oral Immunotherapy for Food Allergy: A Spanish Guideline. Immunotherapy Egg and Milk Spanish Guide (ITEMS Guide). Part I: Cow Milk and Egg Oral Immunotherapy: Introduction, Methodology, Rationale, Current State, Indications, Contraindications, and Oral Immunotherapy Build-up Phase
published pages: 225-237, ISSN: 1018-9068, DOI: 10.18176/jiaci.0177
|Journal of Investigational Allergology and Clinical Immunology 27/4||2019-06-13|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SO-CMA" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SO-CMA" are provided by the European Opendata Portal: CORDIS opendata.
Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and IconographyRead More
The multi-omics role of lipid transfer proteins in lipid metabolismRead More
Wessex–Armorica: Territories, Connections and HierarchiesRead More